Comparison of Adverse Drug Reactions with Donepezil versus Memantine: Analysis of the French Pharmacovigilance Database

被引:11
作者
Babai, Samy [1 ]
Auriche, Pascal [2 ]
Le-Louet, Herve [1 ]
机构
[1] Hop Henri Mondor, Ctr Reg Pharmacovigilance, F-94010 Creteil, France
[2] Afssaps, St Denis, France
来源
THERAPIE | 2010年 / 65卷 / 03期
关键词
pharmacovigilance; adverse drug reactions; memantine; donepezil; Alzheimer disease; SEVERE ALZHEIMERS-DISEASE; CHOLINESTERASE-INHIBITORS; DEMENTIA; MODERATE; PREVALENCE; MANAGEMENT;
D O I
10.2515/therapie/2010008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. Since donepezil and memantine are currently used for treating Alzheimer's disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use. Methods. All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 years were retrospectively analysed. Results. The most frequent adverse drug reactions with donepezil alone and memantine alone were respectively: bradycardia (10% versus 7%), weakness (5% versus 6%) and convulsions (4% versus 3%). Conclusion. The most adverse drug events with donepezil and with memantine are associated with elderly people, even if they do not receive any other treatment. Donepezil and memantine have an acceptable safety profile but physicians should take special care when they prescribe any drug known to cause bradycardia or to reduce the epileptogenic threshold.
引用
收藏
页码:255 / 259
页数:5
相关论文
共 22 条
[1]  
BEGAUD B, 1985, THERAPIE, V40, P111
[2]  
Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub3, 10.1002/14651858.CD001190.pub2]
[3]   Memantine in Moderately-Severe-to-Severe Alzheimer's Disease A Postmarketing Surveillance Study [J].
Clerici, Francesca ;
Vanacore, Nicola ;
Elia, Antonietta ;
Spila-Alegiani, Stefania ;
Pomati, Simone ;
Da Cas, Roberto ;
Raschetti, Roberto ;
Mariani, Claudio .
DRUGS & AGING, 2009, 26 (04) :321-332
[4]   Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment [J].
Dantoine, T ;
Auriacombe, S ;
Sarazin, M ;
Becker, H ;
Pere, JJ ;
Bourdeix, I .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (01) :110-118
[5]   Memantine Dosing in Patients With Dementia [J].
Dolder, Christian ;
Nelson, Michael ;
McKinsey, Jonathan .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 17 (02) :170-173
[6]   Pharmacologic management of Alzheimer disease [J].
Downey, Deborah .
JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (01) :55-59
[7]   Adverse drug reactions: definitions, diagnosis, and management [J].
Edwards, IR ;
Aronson, JK .
LANCET, 2000, 356 (9237) :1255-1259
[8]  
Erkent Ü, 2008, ARZNEIMITTEL-FORSCH, V58, P255, DOI 10.1055/s-0031-1296502
[9]   Global prevalence of dementia: a Delphi consensus study [J].
Ferri, CP ;
Prince, M ;
Brayne, C ;
Brodaty, H ;
Fratiglioni, L ;
Ganguli, M ;
Hall, K ;
Hasegawa, K ;
Hendrie, H ;
Huang, YQ ;
Jorm, A ;
Mathers, C ;
Menezes, PR ;
Rimmer, E ;
Scazufca, M .
LANCET, 2005, 366 (9503) :2112-2117
[10]   Does Memantine induce bradycardia? A study in the French PharmacoVigilance Database [J].
Gallini, Adeline ;
Sommet, Agne ;
Montastruc, Jean-Louis .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (09) :877-881